Jounce Therapeutics, Inc. logo

Jounce Therapeutics, Inc.

Jounce Therapeutics is engaged in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Jounce Therapeutics (NASDAQ: JUNO) is focused on the discovery and development of first-in-class cancer immunotherapiesdesigned to utilize the patients immune system to seek out and attack cancerous cells and tumors. The concept at Jounce is tobuild a pipeline of antibodies and other injectable protein drugs that can spark the immune system to fight cancer cells.

In Dec 2013 Jounce founder Jim Allison won the Breakthrough Prize in Life Sciences for his research on the biology of T cells.In 2014, the National Foundation for Cancer Research (NFCR) awarded him the Szent-Gyorgyi Prize for Progress in Cancer Research that led to the successful development of _immune checkpoint therapy,î and the first drug for the treatment of metastatic melanoma.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”JNCE” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://jouncetx.com
Founded2013
Disease Focus
Development Stage
STOCK CODENASDAQ: JNCE
Address
1030 Massachusetts Avenue ,2138
Cambridge
United States
Email
Contact Number
1-857-259-3840

Jounce Therapeutics (NASDAQ: JUNO) is focused on the discovery and development of first-in-class cancer immunotherapiesdesigned to utilize the patients immune system to seek out and attack cancerous cells and tumors. The concept at Jounce is tobuild a pipeline of antibodies and other injectable protein drugs that can spark the immune system to fight cancer cells.

In Dec 2013 Jounce founder Jim Allison won the Breakthrough Prize in Life Sciences for his research on the biology of T cells.In 2014, the National Foundation for Cancer Research (NFCR) awarded him the Szent-Gyorgyi Prize for Progress in Cancer Research that led to the successful development of _immune checkpoint therapy,î and the first drug for the treatment of metastatic melanoma.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/jounce-therapeutics” connections=”true” suffix=””]

In July 2016, Jounce Therapeutics signs strategic deal with Celgene to develop Next-generation Immuno-oncology Therapies. As per terms Jounce received an upfront payment of $225 Mn, a $36 Mn equity investment and up to an additional $2.3 billion in future milestone payments across all programs included in the collaboration. Also, Celgene to receive options to jointly develop and commercialize Jounces lead product candidate, JTX-2011, and additional innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.

Partnering Activities

Jounces lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells that is believed to stimulate an immune response against a patients cancer.

Jounce is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.

JTX-2011 is expected to enter the clinic in the second half of 2016.

In Dec 2014, Jounce raised $265 Mn through IPO. Jounce was launched in 2013, with $47 million in Series A venture capital financing by Third Rock Ventures.